Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • ascls.org
    • ascls.org

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society for Clinical Laboratory Science
  • ascls.org
    • ascls.org
  • My alerts
  • Log in
  • My Cart
American Society for Clinical Laboratory Science

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • Follow ASCLS on Twitter
  • Visit ASCLS on Facebook
  • Follow ASCLS on Instagram
  • RSS Feed
Research ArticleFocus: Anticoagulant Therapy

Monitoring the Anti-Xa Anticoagulants, from Heparin to Eliquis

George A. Fritsma
American Society for Clinical Laboratory Science January 2013, 26 (1) 48-53; DOI: https://doi.org/10.29074/ascls.26.1.48
George A. Fritsma
The Fritsma Factor, Your Interactive Hemostasis ResourceSM, Fritsma & Fritsma LLC, Birmingham, AL
MS MT (ASCP)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: George@fritsmafactor.com
  • Article
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

  1. George A. Fritsma, MS MT (ASCP)⇑
    1. The Fritsma Factor, Your Interactive Hemostasis ResourceSM, Fritsma & Fritsma LLC, Birmingham, AL
  1. Address for Correspondence: George A. Fritsma MS MT (ASCP), The Fritsma Factor, Your Interactive Hemostasis ResourceSM, Fritsma & Fritsma LLC, 153 Redwood Drive, Birmingham, AL 357173, 205-655-0687, George{at}fritsmafactor.com.
  1. Describe the physiologic action of heparin, low molecular weight heparin, and pentasaccharide on antithrombin and activated coagulation factor X.

  2. Prepare an ex vivo “Brill-Edwards curve” and employs the partial thromboplastin time to monitor unfractionated heparin.

  3. Employ the prothrombinase-induced clotting time and the chromogenic anti-Xa assay to monitor unfractionated heparin, low molecular weight heparin, pentasaccharide, or direct anti-Xa therapy.

Extract

Standard Unfractionated Heparin Therapy Unfractionated heparin (UFH) is a crude mixture of sulfated linear glycosaminoglycans extracted from porcine mucosa composed of an average of 60 saccharide units.1 UFH is one of nature's most negatively charged molecules with a molecular weight of 3000–30,000 Daltons and a median of 15,000 Daltons.2 A pentasaccharide sequence that binds a specific site on plasma antithrombin (AT, antithrombin III, AT III) appears on one-third of UFH molecules. This sequence provides the catalytic anticoagulant action of UFH as it binds its AT receptor site. UFH-bound AT undergoes a conformational change, exposing a second site that covalently inactivates the coagulation pathway serine proteases IIa (thrombin), IXa, Xa, XIa, and XIIa. We take clinical interest only in AT binding of thrombin and Xa, despite its additional properties. Activated AT is a serine protease inhibitor (SERPIN), and the protease binding reaction yields an inactive plasma complex thrombin-antithrombin (TAT).

Heparin supports the TAT “approximation” reaction. When the UFH molecule exceeds 17 linear saccharide units, thrombin assembles on the molecule in approximation to (near) the activated AT. Approximation drives the TAT reaction at four times the rate of the AT-factor Xa reaction because Xa is inactivated only by antithrombin's protease binding site, independent of approximation.

UFH lots are unrefined and vary in MW, molecule length, and anticoagulant efficacy. Individual patient UFH metabolism rates diverge markedly because human plasma and cellular proteins bind heparin at varying rates and concentrations. Consequently, laboratory monitoring is essential to UFH therapy.

Physicians administer UFH intravenously to treat…

ABBREVIATIONS: AMI - acute myocardial infraction; APTT or PTT - activated partial thromboplastin time; AT - antithrombin; CAD - coronary artery disease; DTI - direct thrombin inhibitor; DVT - deep venous thrombosis; FDA - US Food and Drug Administration; GFR - glomerular filtration rate; HIT - heparin-induced thrombocytopenia with thrombosis; LMWH - low molecular weight heparin; PE - pulmonary embolism; PiCT - prothrombinase-induced clotting time; PT - prothrombin time; RI - reference interval; RUO - research use only; SERPIN - serine protease inhibitor; TAT - thrombin-antithrombin; UFH - unfractionated heparin; VTE - venous thromboembolism.

    INDEX TERMS
  • Anticoagulants
  • heparin
  • fondaparinux
  • rivaroxaban
  • apixaban
  • activated partial thromboplastin time
  • anti-Xa heparin assay
  • thrombosis
  • thromboembolic disease
  • coronary artery disease
  1. Describe the physiologic action of heparin, low molecular weight heparin, and pentasaccharide on antithrombin and activated coagulation factor X.

  2. Prepare an ex vivo “Brill-Edwards curve” and employs the partial thromboplastin time to monitor unfractionated heparin.

  3. Employ the prothrombinase-induced clotting time and the chromogenic anti-Xa assay to monitor unfractionated heparin, low molecular weight heparin, pentasaccharide, or direct anti-Xa therapy.

  • © Copyright 2013 American Society for Clinical Laboratory Science Inc. All rights reserved.
PreviousNext
Back to top

In this issue

American Society for Clinical Laboratory Science: 26 (1)
American Society for Clinical Laboratory Science
Vol. 26, Issue 1
Winter 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Society for Clinical Laboratory Science.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Monitoring the Anti-Xa Anticoagulants, from Heparin to Eliquis
(Your Name) has sent you a message from American Society for Clinical Laboratory Science
(Your Name) thought you would like to see the American Society for Clinical Laboratory Science web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Monitoring the Anti-Xa Anticoagulants, from Heparin to Eliquis
George A. Fritsma
American Society for Clinical Laboratory Science Jan 2013, 26 (1) 48-53; DOI: 10.29074/ascls.26.1.48

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Monitoring the Anti-Xa Anticoagulants, from Heparin to Eliquis
George A. Fritsma
American Society for Clinical Laboratory Science Jan 2013, 26 (1) 48-53; DOI: 10.29074/ascls.26.1.48
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Anticoagulant Therapy Overview
  • Monitoring the Direct Thrombin Inhibitors
Show more Focus: Anticoagulant Therapy

Similar Articles

Keywords

  • Anticoagulants
  • heparin
  • fondaparinux
  • rivaroxaban
  • apixaban
  • activated partial thromboplastin time
  • anti-Xa heparin assay
  • thrombosis
  • thromboembolic disease
  • coronary artery disease

© 2025 The American Society for Clinical Laboratory Science

Powered by HighWire